AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Analyst Upgrades and Downgrades

ABBV has been the subject of several research reports. BMO Capital Markets increased their price target on shares of AbbVie from $161.00 to $174.00 and gave the stock an "outperform" rating in a research note on Monday, April 25th. Morgan Stanley reduced their price objective on shares of AbbVie from $191.00 to $188.00 and set an "overweight" rating for the company in a research note on Monday, August 1st. Barclays raised their price objective on shares of AbbVie from $150.00 to $174.00 and gave the company an "equal weight" rating in a research note on Tuesday, April 12th. The Goldman Sachs Group raised their price objective on shares of AbbVie from $122.00 to $140.00 and gave the company a "neutral" rating in a research note on Tuesday, April 12th. Finally, Daiwa Capital Markets lowered shares of AbbVie from an "outperform" rating to a "neutral" rating and set a $150.00 price objective for the company. in a research note on Friday, May 6th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $160.50.

AbbVie Stock Performance

ABBV opened at $140.34 on Tuesday. The company has a current ratio of 0.84, a quick ratio of 0.75 and a debt-to-equity ratio of 4.15. The company has a market cap of $248.14 billion, a price-to-earnings ratio of 19.88, a PEG ratio of 3.88 and a beta of 0.70. The company's 50 day moving average is $147.32 and its 200 day moving average is $150.34. AbbVie has a 12-month low of $105.56 and a 12-month high of $175.91.

AbbVie (NYSE:ABBV - Get Rating) last posted its quarterly earnings data on Friday, July 29th. The company reported $3.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.42 by $0.09. The company had revenue of $14.58 billion for the quarter, compared to the consensus estimate of $14.64 billion. AbbVie had a net margin of 22.03% and a return on equity of 158.41%. The firm's revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm posted $3.11 earnings per share. On average, equities research analysts predict that AbbVie will post 14.05 EPS for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Shareholders of record on Friday, July 15th will be issued a dividend of $1.41 per share. This represents a $5.64 annualized dividend and a yield of 4.02%. The ex-dividend date of this dividend is Thursday, July 14th. AbbVie's dividend payout ratio is currently 79.89%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Henry O. Gosebruch sold 83,960 shares of AbbVie stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the transaction, the executive vice president now owns 16,623 shares of the company's stock, valued at $2,576,565. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Vice Chairman Michael Severino sold 79,801 shares of the business's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $150.90, for a total value of $12,041,970.90. Following the transaction, the insider now owns 152,103 shares of the company's stock, valued at $22,952,342.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Henry O. Gosebruch sold 83,960 shares of the business's stock in a transaction on Monday, May 16th. The stock was sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the completion of the sale, the executive vice president now owns 16,623 shares in the company, valued at approximately $2,576,565. The disclosure for this sale can be found here. Insiders have sold 263,761 shares of company stock valued at $40,500,771 over the last 90 days. 0.08% of the stock is currently owned by corporate insiders.